CJC-1295 Ipamorelin
Wholesale Supply
The definitive GH secretagogue research stack for longevity clinics, anti-aging practices, and regenerative medicine programs. CJC-1295 (no DAC) activates the GHRH receptor pathway. Ipamorelin — the first selective GH secretagogue — activates GHS-R1a via ghrelin mimicry. Dual-receptor synergy with zero cortisol or prolactin stimulation. Research-grade ≥98% purity, full COA every batch.
CJC-1295 Ipamorelin — The #1 GH Secretagogue Stack Explained
The CJC-1295 ipamorelin combination is the most widely used GH secretagogue research stack in longevity medicine and anti-aging clinic wholesale supply. Its clinical dominance is pharmacologically grounded: CJC-1295 (no DAC) and ipamorelin activate two completely distinct receptor systems in the pituitary somatotroph, and published research demonstrates these pathways are synergistic — simultaneous dual-receptor activation produces greater GH axis stimulation than either compound achieves independently.
CJC-1295 without DAC — also called Modified GRF 1-29 or Mod GRF — is a tetrasubstituted analog of the first 29 amino acids of native GHRH. The four amino acid substitutions (positions 2, 8, 15, 27) enhance proteolytic resistance while maintaining high affinity for the GHRH receptor (GHRHR). It activates adenylyl cyclase via Gs protein coupling, increasing intracellular cAMP and PKA, ultimately driving GH gene transcription and amplifying pulse amplitude. Its 30-minute half-life (without DAC) produces pulsatile stimulation that mirrors natural GH secretion patterns — critical for research protocols designed to preserve hypothalamic-pituitary axis integrity.
Ipamorelin (NNC 26-0161) is a synthetic pentapeptide and selective agonist of GHS-R1a — the ghrelin receptor. Designated as “the first selective growth hormone secretagogue” in its 1998 landmark publication in the European Journal of Endocrinology, ipamorelin’s selectivity is its defining characteristic: it stimulates GH release without affecting cortisol, ACTH, prolactin, FSH, LH, or TSH. This clean receptor selectivity — GH stimulation only — is why ipamorelin displaced GHRP-2 and GHRP-6 as the preferred GHRP partner for CJC-1295 in research protocols worldwide.
Dual-Receptor Synergy
CJC-1295 activates GHRH receptors (cAMP/PKA pathway — GH amplitude). Ipamorelin activates GHS-R1a (Ca²⁺/PKC pathway — GH pulse frequency). Different receptors, different second messengers, synergistic outcome. Published research demonstrates the combined stimulation exceeds additive effects of either compound alone.
Ipamorelin’s Selectivity
The critical differentiator from GHRP-2 and GHRP-6: ipamorelin does not stimulate cortisol, ACTH, prolactin, or other pituitary hormones. GH stimulation only. This selectivity — established in the 1998 Raun et al. EJE publication — is the primary reason ipamorelin is the standard GHRP choice for CJC-1295 combination research protocols.
One Vial, One Protocol
Co-lyophilized means both peptides are freeze-dried together in the same vial — one reconstitution delivers the complete 5+5mg research dose. Eliminates dual-vial preparation complexity. For clinic-scale wholesale programs running consistent protocols, the operational simplification is significant.
Clinic & Longevity Staple
90,000+ combined monthly searches. The CJC-1295 ipamorelin stack is the foundational GH secretagogue protocol in longevity medicine wholesale supply — consistent institutional repeat-purchase demand from anti-aging clinics, regenerative medicine practices, and GH axis research programs across the country.
How CJC-1295 + Ipamorelin Work — Dual Pathway Explained
The scientific rationale for this combination is grounded in the two-pathway model of GH secretion. Growth hormone release from pituitary somatotrophs is regulated by two distinct stimulatory systems — the GHRH pathway and the ghrelin/GHRP pathway — operating through separate receptors and separate intracellular signaling cascades. CJC-1295 engages one; ipamorelin engages the other.
Dual
Activation
Combined Effect — Dual-Pathway GH Axis Stimulation
CJC-1295 amplifies GH pulse height (amplitude) via the cAMP/PKA pathway. Ipamorelin modulates pulse timing (frequency) via the Ca²⁺/PKC pathway. Published research in Journal of Clinical Endocrinology & Metabolism demonstrated that CJC-1295 produces pulsatile GH secretion even during continuous stimulation — a critical finding for research protocols studying natural GH axis dynamics. The dual-pathway combination produces synergistic GH stimulation that neither compound achieves alone, with ipamorelin’s selectivity ensuring no off-target pituitary hormone activation.
CJC-1295 No DAC vs With DAC — Which Is Right for Wholesale?
This is the most important product selection question for CJC-1295 wholesale buyers. The DAC (Drug Affinity Complex) modification fundamentally changes CJC-1295’s pharmacokinetic profile — and for ipamorelin combination protocols, no DAC is the correct choice.
CJC-1295 No DAC
Modified GRF 1-29 · Mod GRF
- Half-life: ~30 minutes
- Produces pulsatile GH release
- Mimics natural GH secretion patterns
- Pairs correctly with ipamorelin kinetics
- Standard for combination GH secretagogue protocols
- Also known as: Mod GRF 1-29, Modified GRF, Sermorelin analog
CJC-1295 With DAC
Albumin-binding · Extended t½
- Half-life: 6–8 days (albumin binding)
- Produces continuous GH stimulation
- Does NOT mimic natural pulsatile patterns
- Used for long-acting once-weekly protocols only
- Not appropriate for pairing with ipamorelin in standard protocols
- Available separately — contact B2B desk
Our pre-made CJC-1295 ipamorelin blend uses CJC-1295 no DAC (Modified GRF 1-29) — the correct pharmacokinetic profile for ipamorelin combination protocols. If your research program requires CJC-1295 with DAC as a standalone SKU, contact our B2B desk for separate pricing.
Ipamorelin vs GHRP-2 vs GHRP-6 — Selectivity Comparison
Not all GHRPs are equal. The defining advantage of ipamorelin in the CJC-1295 stack is its receptor selectivity — GH stimulation without triggering cortisol, ACTH, or prolactin. This selectivity, established in a 1998 landmark publication and confirmed in subsequent research, is why ipamorelin replaced earlier GHRPs as the standard partner for GHRH analogs in research protocols.
| Property | Ipamorelin | GHRP-2 | GHRP-6 |
|---|---|---|---|
| GH Stimulation | ✓ Strong | ✓ Strong | ✓ Strong |
| Cortisol Stimulation | ✗ None | ✗ Yes — significant | ✗ Yes — moderate |
| ACTH Stimulation | ✗ None | ✗ Yes | ✗ Yes |
| Prolactin Stimulation | ✗ None | ✗ Yes | ∼ Mild |
| Appetite Stimulation | ✗ Minimal | ∼ Mild | ✗ Significant |
| Selectivity Classification | “First selective GH secretagogue” (Raun et al., 1998) | Non-selective GHRP | Non-selective GHRP |
| Ideal CJC-1295 Partner | ✓ Standard choice | ✗ Off-target effects | ✗ Off-target effects |
CJC-1295 Ipamorelin Blend — Full Specifications
CJC-1295 No DAC Component
| Also Known As | Modified GRF 1-29, Mod GRF, [D-Ala², Ala⁸,⁹,¹⁵]GHRH-(1-29)NH₂ |
| Amino Acids | 29 |
| Molecular Weight | 3,367.97 Da |
| CAS Number | 863288-34-0 |
| Target | GHRH Receptor (GHRHR) — Gs coupled |
| Half-life | ~30 minutes (no DAC) |
| Amount Per Vial | 5mg |
Ipamorelin Component
| Also Known As | NNC 26-0161, Ipamorelin acetate |
| Amino Acids | 5 (pentapeptide) |
| Molecular Weight | 711.86 Da |
| CAS Number | 170851-70-4 |
| Target | GHS-R1a (Ghrelin Receptor) — Gq coupled |
| Selectivity | GH only — no cortisol, ACTH, or prolactin |
| Amount Per Vial | 5mg |
Blend & Format
| Total Content | 10mg (5mg CJC-1295 + 5mg Ipamorelin) |
| Form | Co-lyophilized powder |
| Ratio | 1:1 (equal mass) |
| Solubility | Bacteriostatic water |
| Storage | -20°C · up to 24 months |
| Post-reconstitution | 4°C · use within 28 days |
Quality Standards
| HPLC Purity | ≥98% (both peptides verified) |
| Identity | Mass spec for each component |
| Endotoxin | <1 EU/mg (LAL method) |
| Sterility | Sterile-filtered, aseptic fill |
| Water Content | <5% (Karl Fischer) |
| Residual Solvents | ICH Q3C compliant |
CJC-1295 Ipamorelin Wholesale Price — Volume Tiers 2026
Structured for clinic-scale and institutional wholesale buyers. All tiers include full dual-component COA documentation.
| Quantity | Total Price | Per Vial | Per mg (total) | Availability |
|---|---|---|---|---|
| CJC-1295 / Ipamorelin 5+5mg × 1 | $61 | $61 | $6.10 / mg | ✓ In Stock |
| × 10 vialsCLINIC PACK | $550 | $55 | $5.50 / mg | ✓ In Stock |
| × 25 vials | $1,275 | $51 | $5.10 / mg | ✓ In Stock |
| × 50 vials | $2,400 | $48 | $4.80 / mg | ✓ In Stock |
| × 100+ vials | Contact | Custom | Custom rate | ✓ In Stock |
CJC-1295 & Ipamorelin in Published Research
Both peptides have strong independent research bases. Their combination is supported by the two-pathway synergy model documented across the GH secretagogue literature.
CJC-1295 Human Pharmacokinetics — The Key Clinical Publication
Ionescu & Frohman (2006, Journal of Clinical Endocrinology & Metabolism) demonstrated that pulsatile GH secretion persists during continuous CJC-1295 stimulation — a finding critical to understanding the compound’s research profile. The study showed dose-dependent increases in GH and IGF-1 levels and established that CJC-1295 without DAC maintains physiological GH release patterns. Alba et al. (2006, AJPEM) demonstrated CJC-1295 normalizes growth in GHRH knockout mouse models.
Published in J. Clin. Endocrinol. Metab., Am. J. Physiol. Endocrinol. Metab., 2006
Ipamorelin — “The First Selective Growth Hormone Secretagogue”
The landmark 1998 Raun et al. publication in European Journal of Endocrinology formally established ipamorelin’s selectivity profile — demonstrating GH stimulation comparable to GHRP-6 with no significant effects on cortisol, ACTH, prolactin, or other pituitary hormones across multiple animal model studies. This selectivity paper is the most-cited reference in ipamorelin wholesale and clinical literature, and is the reason ipamorelin became the standard GHRP choice for CJC-1295 combination protocols.
Raun K et al., European Journal of Endocrinology, 1998
Dual-Pathway Synergy — GHRH + GHRP Combination Research
The mechanistic rationale for combining GHRH analogs with GHRPs is well-established in the endocrinology literature predating CJC-1295. Bowers et al. (Endocrinology, 1990) demonstrated that GHRH and GHRP pathways act synergistically at both pituitary and hypothalamic levels — the cAMP/PKA pathway (GHRHR) and the Ca²⁺/PKC pathway (GHS-R1a) produce additive-to-synergistic GH stimulation when activated simultaneously. This foundational dual-pathway research is the scientific basis for all GHRH analog + GHRP combination protocols including CJC-1295 ipamorelin.
Bowers CY et al., Endocrinology, 1990; Teichman SL et al., J. Clin. Endocrinol. Metab., 2006
GH Axis, IGF-1, & Downstream Research Applications
Published research has studied CJC-1295 and ipamorelin individually and in GH secretagogue combinations for downstream GH axis effects including IGF-1 modulation, lean body composition changes in animal models, bone density in glucocorticoid-exposed rats (ipamorelin), and gastric motility research. The GH axis research application space for this stack encompasses longevity, anti-aging, metabolic, musculoskeletal, and endocrine research programs.
Multiple publications including Andersen et al., Growth Hormone & IGF Research; Greenwood-Van Meerveld et al., Journal of Experimental Pharmacology
Blend Quality Standards
A GH secretagogue blend COA must verify both peptide components independently — not report a single aggregate figure. Both CJC-1295 and ipamorelin need separate mass spectrometry identity confirmation given their very different molecular weights (3,367 Da vs 711 Da).
Dual COA
HPLC purity and mass spec identity confirmed for both CJC-1295 and ipamorelin independently.
Both ≥98% HPLC
CJC-1295 no DAC and ipamorelin each verified at ≥98% before co-lyophilization.
Endotoxin + Sterility
LAL endotoxin <1 EU/mg. Sterile-filtered, aseptic fill confirmed on blend.
Co-Lyophilized
Both peptides combined prior to lyophilization. Consistent ratio delivery confirmed.
Cold-Chain Shipping
Ships cold-chain. Both peptides stable co-lyophilized at -20°C up to 24 months.
48h Fulfillment
In-stock orders ship within 48 business hours with cold-chain manifest.
Who Buys CJC-1295 Ipamorelin Wholesale
The GH secretagogue stack’s consistent demand is driven by longevity and anti-aging institutional buyers running recurring research protocols. Not available to the general public.
Longevity & Anti-Aging Clinics
The primary wholesale buyer category. GH secretagogue protocols are a core offering of longevity medicine programs, driving consistent monthly ordering cycles.
Regenerative Medicine Practices
Regenerative and integrative medicine practices incorporating GH axis research protocols under physician oversight.
Compounding Pharmacies
503A and 503B pharmacies with GH secretagogue compounding programs requiring research-grade bulk ingredient supply.
Research Institutions
Universities and CROs with active endocrinology, GH axis, IGF-1, and pituitary somatotroph research programs.
Sports Medicine Programs
Performance and recovery research programs studying GH secretagogue effects on lean body composition, musculoskeletal repair, and recovery markers.
Peptide Distributors
B2B distributors supplying downstream licensed research buyers. CJC-1295 ipamorelin is a high-velocity base SKU in any GH secretagogue catalog.
CJC-1295 Ipamorelin Wholesale — FAQ
Research Use Only: CJC-1295 ipamorelin blend and all products on this page are sold strictly for in vitro research and laboratory use only. Not intended for human or veterinary use, consumption, injection, or therapeutic application. Not FDA-approved drugs or dietary supplements. Neither CJC-1295 nor ipamorelin has received FDA approval as a therapeutic agent. No claims are made regarding safety, efficacy, or therapeutic benefit in humans or animals. Buyers are solely responsible for compliance with all applicable federal, state, and local laws. By purchasing, you confirm you are a licensed researcher or qualified institutional buyer acting within the scope of a legitimate research program.
Reviews
There are no reviews yet.